HEAL Initiative: Opioid Exposure and Effects on Placenta Function, Brain Development, and Neurodevelopmental Outcomes (R01 Clinical Trial Not Allowed) | RFA HD 23 030

Opportunity Information: Apply for RFA HD 23 030

The National Institutes of Health (NIH) is soliciting R01 research grant applications under the HEAL Initiative for studies that examine how opioid exposure during pregnancy affects placental function, early brain development, and neurodevelopmental outcomes from the prenatal period through the first year of life. The scientific emphasis is on understanding the biological and developmental consequences of opioids either by themselves or when combined with other commonly misused substances, recognizing that polysubstance exposure is a frequent real-world scenario. In practical terms, the FOA is looking for mechanistic, developmental, and translational research that can clarify how in utero and early-life opioid exposure may alter the placenta (the interface that regulates oxygen, nutrients, hormones, immune signaling, and xenobiotic transfer) and how those placental changes may shape fetal and infant brain development and later neurodevelopmental trajectories.

A key boundary for this opportunity is that clinical trials are not allowed. Applicants need to structure their work as non-trial research (for example, observational human cohort studies, analyses of existing biospecimens or datasets, or preclinical/model-based studies), rather than interventional studies that prospectively assign participants to an intervention to evaluate health-related outcomes. The FOA explicitly flags that investigators who are proposing Basic Experimental Studies with Humans (BESH) should instead look to the companion announcement, RFA-HD-23-032, which requires BESH. This distinction matters because NIH uses BESH to describe certain types of prospective, basic-mechanistic studies in humans that may involve manipulation of conditions or exposures for the purpose of understanding fundamental biology, even when they are not traditional clinical efficacy trials. In other words, this RFA is positioned for research on exposure effects and mechanisms without moving into the territory NIH classifies as a clinical trial for this funding line.

The announcement is identified as RFA-HD-23-030 and uses the R01 activity code, meaning it supports discrete, hypothesis-driven projects that typically span multiple years and are intended to generate substantial advances in knowledge. It sits within NIH and aligns with the broader HEAL (Helping to End Addiction Long-term) Initiative, which is a cross-NIH effort aimed at addressing the opioid crisis through improved prevention, treatment, and understanding of opioid-related harms. The activity categories listed in the source data reflect NIH mission areas spanning health and human development (with CFDA numbers 93.242, 93.273, 93.279, 93.853, 93.865), which is consistent with the focus on pregnancy, placenta biology, infant development, and neurodevelopment.

Eligible applicants are broad and include many standard U.S.-based research-performing organizations and governmental entities. These include state, county, city/township, and special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized tribal governments; tribal organizations that are not federally recognized; public housing authorities/Indian housing authorities; and a wide range of nonprofit organizations (both 501(c)(3) and non-501(c)(3)). The FOA also allows for-profit organizations (other than small businesses) and small businesses, along with an “other” category that can cover additional eligible entities as defined by NIH policy. The announcement also highlights “other eligible applicants” to encourage participation from institutions that serve populations often underrepresented in biomedical research infrastructure, including Alaska Native and Native Hawaiian Serving Institutions, AANAPISI institutions, Hispanic-serving institutions, Historically Black Colleges and Universities (HBCUs), and Tribally Controlled Colleges and Universities (TCCUs). Faith-based or community-based organizations and eligible federal agencies are also called out, along with U.S. territories or possessions, reflecting an intent to support geographically and institutionally diverse research capacity.

At the same time, there are clear restrictions on foreign participation. Non-domestic (non-U.S.) entities, whether foreign organizations or foreign institutions, are not eligible to apply as the applicant organization. In addition, non-domestic components of U.S. organizations are not eligible to apply. However, “foreign components” are allowed as defined in the NIH Grants Policy Statement, meaning a U.S.-based applicant may include certain international elements (such as specific collaborations, performance sites, or subawards) if they meet NIH’s definition and are well-justified scientifically. This setup is common in NIH RFAs that want to keep primary award accountability within the U.S. while still permitting strategically necessary international work.

From an administrative standpoint, the opportunity is categorized as discretionary and uses the grant funding instrument. The source data lists an original closing date of 2022-12-07 and a creation date of 2022-08-29. The award ceiling and expected number of awards are not specified in the provided data excerpt, which typically means applicants need to consult the full FOA text and NIH institute/center guidance for budget expectations, limits, and programmatic priorities. Overall, the opportunity is designed for investigators who can rigorously study opioid-related biological effects across the maternal-placental-fetal axis and connect those effects to measurable brain and neurodevelopmental outcomes in early life, while staying within a non-clinical-trial research framework.

• The National Institutes of Health in the education, health, income security and social services sector is offering a public funding opportunity titled "HEAL Initiative: Opioid Exposure and Effects on Placenta Function, Brain Development, and Neurodevelopmental Outcomes (R01 Clinical Trial Not Allowed)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.242, 93.273, 93.279, 93.853, 93.865.
• This funding opportunity was created on 2022-08-29.
• Applicants must submit their applications by 2022-12-07. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for RFA HD 23 030

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: